Stage IV KRAS Breast Cancer: Lauren's Patient Story

Patient Info: Lauren, Female | Stage IV

Biomarkers: KRAS mutation in colon cancer context

Metastatic Site: Abdominal lining; spine

As of September 2024, Lauren was living with a history of Stage IV colon cancer and recurrent metastatic breast cancer in the spine, with low colon tumor markers, recurring spinal spots, and PET scans every 3 months.

The Patient StoryRead more →

Stage IV Breast Cancer: Lourdes's Patient Story

Patient Info: Lourdes Monje, Under 40 | Stage IV

Metastatic Site: lung

Lourdes is receiving investigational treatment through a clinical trial, with manageable side effects, while continuing to work and spend time with family and friends.

Stage 4 breast cancer: ongoing treatment with multi-line chemotherapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: hormone receptor-negative; HER2 2+. 2011 recurrence: ER 10%; PR 70%; HER2 2+.

Metastatic Site: pleura/pleural effusion; lung

Metastatic breast cancer with malignant pleural effusion achieved complete response after chemotherapy and long-term endocrine therapy; PET-CT in October 2023 still showed complete response, with ongoing cardiac and bone-health management.

PubMed CentralRead more →

Invasive Lobular Carcinoma: Kristie's Survivor Story

Patient Info: Kristie, Female

As of August 2024, Kristie was focused on survivorship and advocacy after extensive ILC treatment that included 20 weeks of chemotherapy, 25 radiation treatments, 2 years on Verzenio, estrogen blockers, and 5 surgeries.

Lobular Breast Cancer AllianceRead more →

Triple-negative breast cancer: partial response to immunotherapy combination

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: Initial tumor: ER-negative; PR-negative; HER2-negative; Ki-67 >80%

Metastatic Site: left lung, neck lymph nodes, mediastinal lymph nodes

Metastatic triple-negative breast cancer had a partial response after 9 months of pembrolizumab plus MK-4830, with reduced tumor burden, decreased lung and mediastinal metastases, and no new metastatic lesions; immunotherapy continued after prednisone controlled a grade 2 lichenoid eruption.

PubMed CentralRead more →

Right-Sided Ductal Carcinoma in Situ Before a Second Breast Cancer

Patient Info: Anonymized, female, 60s

Biomarkers: ER-positive; PR-positive; HER2 1+

A woman treated for right-sided ductal carcinoma in situ in 2018 later developed a separate invasive cancer in the opposite breast.

PubMed CentralRead more →

HER2-Positive Breast Cancer That Spread to the Cervix

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: HER2-positive; ER and PR less than 1% in the left breast tumor

Metastatic Site: cervix, esophagus, mediastinal lymph nodes

Cervical metastasis showed a local complete response after brachytherapy, but systemic disease later progressed to the esophagus. She died after 4 months of nutritional support and palliative treatment.

PubMed CentralRead more →

Stage I Invasive Lobular Carcinoma: Jessica's Patient Story

Patient Info: Jessica, Female, 40s | Stage I

Biomarkers: Myriad genetic testing negative; Oncotype DX score 19; RSClin recurrence risk 19%; isolated tumor cells around 1 sentinel lymph node without invasion

As of July 2024, Jessica had completed bilateral mastectomy for Stage IB ILC and was moving forward with radiation and long-term hormone suppression after chemotherapy was not recommended.

Lobular Breast Cancer AllianceRead more →

Rare acinic cell breast cancer treated with mastectomy

Patient Info: Anonymized, Female, Under 40

Biomarkers: Triple-negative; pMMR/MSS; Ki-67 very high. TP53 and several other mutations reported; no gene fusion/rearrangement found.

Alive for 43 months with no metastasis or recurrence after surgery, 8 cycles of epirubicin/cyclophosphamide, and radiotherapy for breast acinic cell carcinoma with high-grade solid transformation.

PubMed CentralRead more →

Stage IV Breast Cancer: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive breast cancer; specific receptor details not reported

Metastatic Site: bone: rib, spine, pelvis

As of July 2024, Samantha was living with Stage IV hormone-positive breast cancer with bone metastases. Current treatment was working in most areas, but a breast tumor continued to grow and was surgically removed; ongoing treatment and 3-month scans were reported.

YouTube — The Patient StoryRead more →

HR-positive HER2-negative metastatic breast cancer: bone metastases managed with sequential endocrine therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER 90%+, PR 80%+, HER2-. CA 15-3 was tracked during treatment.

Metastatic Site: skull base; spine; sternum; ribs; left iliac bone;…

Metastatic HR-positive, HER2-negative breast cancer remained under active management; after earlier progression, palbociclib plus fulvestrant and zoledronic acid produced stable/remission findings on PET/CT at 3 months and again 1 year later, with continued 3-month follow-up recommended.

PubMed CentralRead more →

Stage 4 luminal A breast cancer: tumor regression on hormone therapy

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative

Metastatic Site: skin, soft tissue, lungs

Metastatic Luminal A breast cancer involving skin/soft tissue and lungs showed regressing tumors and stable lung metastasis after 3 months of anti-hormone therapy plus capecitabine; longer-term control was not reported.

PubMed CentralRead more →

Finding A Lump To BREAST CANCER!

Patient Info: Kelsey Harrison, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of July 2024, Kelsey had completed chemotherapy, double mastectomy with axillary lymph-node removal, and radiation, and was continuing tamoxifen plus Lupron ovarian suppression with additional planned systemic therapy.

The Patient StoryRead more →

HER2-positive breast cancer: surgery after neoadjuvant therapy

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER 1% weakly positive; PR-negative; HER2-positive

No evidence of disease on follow-up while taking anastrozole after pathologic complete response to neoadjuvant T-DM1, lumpectomy/SLNB, radiotherapy, and adjuvant trastuzumab for Stage I HER2-positive breast cancer.

PubMed CentralRead more →

HER2-positive Stage I breast cancer: residual microinvasion after neoadjuvant T-DM1

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: ER-negative; PR-negative; HER2-positive

No evidence of disease on follow-up after neoadjuvant T-DM1, lumpectomy/SLNB showing only residual microinvasion/DCIS, continued adjuvant T-DM1 to 17 total cycles, and 52.5 Gy radiotherapy.

PubMed CentralRead more →

Stage II Invasive Lobular Carcinoma: Lizzie's Survivor Story

Patient Info: Lizzie, Female | Stage II

Lizzie completed mastectomy, reconstruction-related surgery and 5 weeks of radiation. She remained on a planned 10-year course of an aromatase inhibitor and became active in breast cancer research advocacy.

Lobular Breast Cancer AllianceRead more →

Stage IV triple-negative breast cancer in remission: CBD and exercise for neuropathy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative breast cancer. Blood and immune inflammation measures were tracked during neuropathy care.

Metastatic Site: liver

She was in remission for more than 5 years after Stage IV breast cancer with a solitary liver metastasis, while later managing chemotherapy-induced peripheral neuropathy with CBD and an exercise program that improved symptoms and function.

PubMed CentralRead more →

Stage 3 breast cancer: pathologic complete response to neoadjuvant chemotherapy

Patient Info: Anonymized, Female, Under 40

Biomarkers: ER-positive, PR-negative, HER2-negative breast cancer with very high Ki-67. MammaPrint high-risk/basal type; hereditary testing negative.

Free of recurrence at last follow-up after neoadjuvant pembrolizumab plus chemotherapy, breast-conserving surgery with RCB-0/pathologic complete response, adjuvant radiation, and adjuvant pembrolizumab.

PubMed CentralRead more →

Stage 4 breast cancer: hip reconstruction preserves mobility

Patient Info: Anonymized, Female, 50s | Stage IV

Metastatic Site: bone (right acetabulum/pelvis: ilium, ischium,…

As of May 2024, 2 years after reconstruction for metastatic breast cancer involving the right acetabulum/pelvis, she had no recurrence of hip pain and had returned to baseline function; overall systemic cancer response was not reported.

PubMed CentralRead more →

Secretory breast cancer: mastectomy and radiotherapy to no evidence of disease

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER-negative; PR-negative; HER2-negative; Ki-67 50%; tumor-infiltrating lymphocytes 60%

As of May 2024, 6 months after mastectomy and adjuvant radiotherapy for pT2N0M0 triple-negative secretory breast cancer, clinical examination and imaging showed no evidence of relapse.

PubMed CentralRead more →

Stage IV Invasive Lobular Carcinoma: Melissa's Patient Story

Patient Info: Melissa Adams, Female | Stage IV

Melissa’s breast cancer progressed after maintenance hormone therapy and was reassigned as Stage IV. She describes living with incurable disease while focusing on keeping the cancer at bay and staying engaged with family, church, and advocacy.

Stage III Inflammatory Breast Cancer: Katrece's Patient Story

Patient Info: Katrece Nolen, Female | Stage III

More than 10 years after her diagnosis, Katrece was taking medication intended to reduce recurrence risk and remained active in advocacy for people with inflammatory breast cancer.

Triple-Negative Breast Cancer: Samantha's Survivor Story

Patient Info: Samantha Salway, Female, Under 40

Biomarkers: ER-negative; PR-negative; HER2-negative

As of May 2024, Samantha had delivered a healthy baby, completed chemotherapy, lumpectomy, radiation and additional chemotherapy, had no current evidence of cancer, and remained under close monitoring.

Cleveland ClinicRead more →

MSI-High Metastatic Hormone-Receptor-Positive Breast Cancer Responding to Pembrolizumab

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; MSI-high; BRCA mutation-negative

Metastatic Site: bone, para-aortic lymph nodes, brain

Pembrolizumab produced marked improvement in metastatic bone and nodal disease. After 1 year it was stopped because of appetite loss; 8 months later she was symptom-free and back at work on endocrine therapy, although asymptomatic brain metastases were documented.

PubMed CentralRead more →